List of Lamictal Xr drug patents
Lamictal Xr is owned by Glaxosmithkline Llc.
Lamictal Xr contains Lamotrigine.
Lamictal Xr has a total of 2 drug patents out of which 0 drug patents have expired.
Lamictal Xr was authorised for market use on 29 May, 2009.
Lamictal Xr is available in tablet, extended release;oral dosage forms.
The generics of Lamictal Xr are possible to be released after 14 June, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144547 | GLAXOSMITHKLINE LLC | Oral dosage form for controlled drug release |
Sep, 2023
(7 months from now) | |
| US8637512 | GLAXOSMITHKLINE LLC | Formulations and method of treatment |
Jun, 2028
(5 years from now) | |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 29 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic